Literature DB >> 22461186

Serum levels of selected chemokines in systemic lupus erythematosus patients.

Eugeniusz Hrycek1, Andrzej Franek, Edward Błaszczak, Justyna Dworak, Antoni Hrycek.   

Abstract

Chemokines promote leukocyte traffic into the site of inflammation. Serum levels of monocyte chemotactic protein 1 (MCP-1), stromal cell-derived factor-1 (SDF-1), interferon-gamma-inducible protein 10 (IP-10), and interleukin-8 (IL-8) were evaluated in 48 treated women with systemic lupus erythematosus (SLE) and mild-to-moderate disease severity. The results were compared between the whole SLE group and the control (29 women). The relationships between chemokines, their concentrations, and peripheral blood leukocyte count and between the chemokines and individual leukocyte populations (polymorphonuclear leukocytes-PMNs, lymphocytes-Ls, monocytes-Ms, eosinophils) counts were determined. The relationships between the analyzed chemokines were also determined in the control. SLE subjects had significantly higher MCP-1, SDF-1, IP-10, and lower IL-8 concentrations compared to the control. Moderate, positive correlations between MCP-1/SDF-1, SDF-1/IP-10 and a negative correlation between MCP-1/IL8 were observed in the patient group. Moderate, negative correlations were found between SDF-1/total leukocyte count, SDF-1/absolute number of PMNs as well as between IP-10/total leukocyte count, IP-10/absolute PMNs, Ls, and Ms counts in peripheral blood of SLE group. We suggest that the obtained results and correlations observed between the examined parameters might be used to monitor SLE course and progression. However, further randomized clinical studies should be carried out on in untreated and treated patients with SLE.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22461186     DOI: 10.1007/s00296-012-2393-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  23 in total

Review 1.  Chemokines in rheumatic diseases.

Authors:  Zoltán Szekanecz; Gabriella Szücs; Sándor Szántó; Alisa E Koch
Journal:  Curr Drug Targets       Date:  2006-01       Impact factor: 3.465

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Circulating levels of beta-chemokines in systemic lupus erythematosus.

Authors:  H Kaneko; H Ogasawara; T Naito; H Akimoto; S Lee; T Hishikawa; I Sekigawa; Y Tokano; Y Takasaki; S I Hirose; H Hashimoto
Journal:  J Rheumatol       Date:  1999-03       Impact factor: 4.666

4.  Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus.

Authors:  L C W Lit; C K Wong; L S Tam; E K M Li; C W K Lam
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

5.  Effect of cancer chemotherapeutic agents on the chemiluminescence of human granulocytes.

Authors:  M C Matamoros; B K Walker; K Van Dyke; C J Van Dyke
Journal:  Pharmacology       Date:  1983       Impact factor: 2.547

6.  Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide.

Authors:  Antoni Hrycek; Grazyna Pochopień-Kenig; Joanna Scieszka
Journal:  Autoimmunity       Date:  2007-05       Impact factor: 2.815

Review 7.  Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus.

Authors:  Benjamin F Chong; Chandra Mohan
Journal:  Expert Opin Ther Targets       Date:  2009-10       Impact factor: 6.902

8.  Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.

Authors:  Jason W Bauer; Michelle Petri; Franak M Batliwalla; Thearith Koeuth; Joseph Wilson; Catherine Slattery; Angela Panoskaltsis-Mortari; Peter K Gregersen; Timothy W Behrens; Emily C Baechler
Journal:  Arthritis Rheum       Date:  2009-10

9.  Phagocytic capacity of human leukocytes preincubated with Imuran and prednisone.

Authors:  D Kotulová; J Stefanovic
Journal:  J Hyg Epidemiol Microbiol Immunol       Date:  1983

10.  Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus.

Authors:  Andrew Wang; Philippe Guilpain; Benjamin F Chong; Sandrine Chouzenoux; Loïc Guillevin; Yong Du; Xin J Zhou; Fangming Lin; Anna-Marie Fairhurst; Christopher Boudreaux; Christian Roux; Edward K Wakeland; Laurie S Davis; Frederic Batteux; Chandra Mohan
Journal:  Arthritis Rheum       Date:  2010-11
View more
  8 in total

1.  Expression profiles of Th17 pathway related genes in human systemic lupus erythematosus.

Authors:  Hai-Feng Pan; Rui-Xue Leng; Chen-Chen Feng; Xiang-Pei Li; Gui-Mei Chen; Bao-Zhu Li; Wang-Dong Xu; Song Guo Zheng; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2012-10-09       Impact factor: 2.316

Review 2.  The non-haemostatic role of platelets in systemic lupus erythematosus.

Authors:  Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 3.  Chemokines in rheumatic diseases: pathogenic role and therapeutic implications.

Authors:  Yoshishige Miyabe; Jeffrey Lian; Chie Miyabe; Andrew D Luster
Journal:  Nat Rev Rheumatol       Date:  2019-11-08       Impact factor: 20.543

4.  Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis.

Authors:  Pongpratch Puapatanakul; Sonchai Chansritrakul; Paweena Susantitaphong; Thornthun Ueaphongsukkit; Somchai Eiam-Ong; Kearkiat Praditpornsilpa; Wonngarm Kittanamongkolchai; Yingyos Avihingsanon
Journal:  Int J Mol Sci       Date:  2019-10-08       Impact factor: 5.923

Review 5.  Diagnostic test accuracy of novel biomarkers for lupus nephritis-An overview of systematic reviews.

Authors:  Juliana de Andrade Rebouças Guimarães; Silvania da Conceição Furtado; Ana Cyra Dos Santos Lucas; Bruno Mori; José Fernando Marques Barcellos
Journal:  PLoS One       Date:  2022-10-10       Impact factor: 3.752

6.  Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma.

Authors:  Kelsey E Magee; Christina E Kelsey; Katherine L Kurzinski; Jonhan Ho; Logan R Mlakar; Carol A Feghali-Bostwick; Kathryn S Torok
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

7.  Serum protein pattern associated with organ damage and lupus nephritis in systemic lupus erythematosus revealed by PEA immunoassay.

Authors:  Anna Petrackova; Andrea Smrzova; Petr Gajdos; Marketa Schubertova; Petra Schneiderova; Pavel Kromer; Vaclav Snasel; Martina Skacelova; Frantisek Mrazek; Josef Zadrazil; Pavel Horak; Eva Kriegova
Journal:  Clin Proteomics       Date:  2017-10-03       Impact factor: 3.988

8.  Centrally Acting Angiotensin-Converting Enzyme Inhibitor Suppresses Type I Interferon Responses and Decreases Inflammation in the Periphery and the CNS in Lupus-Prone Mice.

Authors:  Cassandra Nocito; Cody Lubinsky; Michelle Hand; Sabeeya Khan; Tulsi Patel; Alecia Seliga; Malika Winfield; Viviana Zuluaga-Ramirez; Nicole Fernandes; Xiangdang Shi; Ellen M Unterwald; Yuri Persidsky; Uma Sriram
Journal:  Front Immunol       Date:  2020-09-15       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.